8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Anaphylaxis in Poland: the epidemiology and direct costs

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Epidemiological data on anaphylaxis have been underestimated both in Poland and worldwide.

          Aim

          To evaluate the prevalence of anaphylaxis in Poland, including a classification by gender, age and residential region.

          Material and methods

          The data used in the analysis were derived from two sources, the National Health Fund records of healthcare services for 2008–2015 (official statistics) and a questionnaire-based survey conducted in 2015 on a sample of 305 allergists practicing in different regions of Poland.

          Results

          In 2015, 3144 people received treatment for anaphylactic shock (T78.0, T78.2, T80.5, T88.6) with an estimated prevalence rate of anaphylaxis of 8.2 per 100,000 (8.4 for females and 7.9 for males). The highest prevalence rate was found for women aged 50–54 years (14.5 per 100,000). There was a very large difference in the prevalence of anaphylaxis between rural and urban areas (13.1 vs. 0.8 per 100,000). In 2015, the Polish NHF spent PLN 3.5 million (EUR 835,000) on the management of anaphylaxis. Of the allergists surveyed, 73% had been currently managing patients who had experienced anaphylactic shock. The most common causes of anaphylaxis included insect venom (41.4%), food (29.8%) and drugs (17.4%).

          Conclusions

          A central anaphylaxis registry should be established in Poland. This is the only approach that would allow collecting a wide range of reliable information on the cases, management and consequences of anaphylaxis. Ongoing management of patients who have experienced anaphylactic shock should be improved.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          The epidemiology of anaphylaxis in Europe: a systematic review.

          Anaphylaxis is an acute, potentially fatal, multi-organ system, allergic reaction caused by the release of chemical mediators from mast cells and basophils. Uncertainty exists around epidemiological measures of incidence and prevalence, risk factors, risk of recurrence, and death due to anaphylaxis. This systematic review aimed to (1) understand and describe the epidemiology of anaphylaxis and (2) describe how these characteristics vary by person, place, and time. Using a highly sensitive search strategy, we identified systematic reviews of epidemiological studies, descriptive and analytical epidemiological investigations, and studies involving analysis of routine data. Our searches identified a total of 5,843 potentially eligible studies, of which 49 satisfied our inclusion criteria. Of these, three were suitable for pooled estimates of prevalence. The incidence rates for all-cause anaphylaxis ranged from 1.5 to 7.9 per 100,000 person-years. These data indicated that an estimated 0.3% (95% CI 0.1-0.5) of the population experience anaphylaxis at some point in their lives. Food, drugs, stinging insects, and latex were the most commonly identified triggers. Anaphylaxis is a common problem, affecting an estimated 1 in 300 of the European population at some time in their lives. Future research needs to focus on better understanding of the trends across Europe and identifying those most likely to experience fatal reactions. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project.

            Reported incidences of anaphylaxis range from 3.2 to 20 per 100,000 population. The incidence and trend over time has meaningful public health implications but has not been well characterized because of a lack of a standard definition and deficiencies in reporting of events. We sought to determine the incidence and cause of anaphylaxis over a 10-year period. We performed a population-based incidence study that was conducted in Rochester, Minnesota, from 1990 through 2000. Anaphylaxis episodes were identified on the basis of symptoms and signs of mast cell and basophil mediator release plus mucocutaneous, gastrointestinal tract, respiratory tract, or cardiovascular system involvement. Two hundred eleven cases of anaphylaxis were identified (55.9% in female subjects). The mean age was 29.3 years (SD, 18.2 years; range, 0.8-78.2 years). The overall age- and sex-adjusted incidence rate was 49.8 (95% CI, 45.0-54.5) per 100,000 person-years. Age-specific rates were highest for ages 0 to 19 years (70 per 100,000 person-years). Ingested foods accounted for 33.2% (70 cases), insect stings accounted for 18.5% (39 cases), medication accounted for 13.7% (29 cases), radiologic contrast agent accounted for 0.5% (1 case), "other" causes accounted for 9% (19 cases), and "unknown" causes accounted for 25.1% (53 cases). The "other" group included cats, latex, cleaning agents, environmental allergens, and exercise. There was an increase in the annual incidence rate during the study period from 46.9 per 100,000 persons in 1990 to 58.9 per 100,000 persons in 2000 (P = .03). The overall incidence rate is 49.8 per 100,000 person-years, which is higher than previously reported. The annual incidence rate is also increasing. Food and insect stings continue to be major inciting agents for anaphylaxis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              First European data from the network of severe allergic reactions (NORA).

              Occurrence, elicitors and treatment of severe allergic reactions are recognized and reported differently between countries. We aimed to collect standardized data throughout Europe on anaphylaxis referred for diagnosis and counselling.
                Bookmark

                Author and article information

                Journal
                Postepy Dermatol Alergol
                Postepy Dermatol Alergol
                PDIA
                Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii
                Termedia Publishing House
                1642-395X
                2299-0046
                31 December 2017
                December 2017
                : 34
                : 6
                : 573-579
                Affiliations
                [1 ]Department of Internal Diseases, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine, Warsaw, Poland
                [2 ]Department of the Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland
                [3 ]Department of Quality of Medical Services, Procedures and Standards, Faculty of Health Sciences, Medical University of Lodz, Lodz, Poland
                [4 ]Department of Analyses and Strategies, National Health Fund, Warsaw, Poland
                [5 ]Department of Gerontology, Public Health, and Didactics, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
                [6 ]Department of Healthcare Organizations and Medical Certification, Centre of Postgraduate Medical Education, Warsaw, Poland
                Author notes
                Address for correspondence: Filip Raciborski PhD, Department of the Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, 1 a Banacha St, 02-091 Warsaw, Poland. phone: +48 22 599 20 39. e-mail: filip.raciborski@ 123456wum.edu.pl
                Article
                30710
                10.5114/pdia.2017.70361
                5799754
                29422823
                213a7997-d62b-4cc9-b050-1dd63bde9100
                Copyright: © 2017 Termedia Sp. z o. o.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

                History
                : 17 October 2016
                : 24 December 2016
                Categories
                Original Paper

                anaphylaxis (anaphylactic shock),epidemiology,nhf (nfz),costs,management

                Comments

                Comment on this article